SOURCE: MedPage Today
DATE: November 19, 2009
EXCERPT: "A subset analysis of data from the JUPITER trial indicates that apparently healthy women treated with rosuvastatin (Crestor) reduced their relative risk of major cardiovascular events by 46%, slightly higher than the 42% reduction seen in men." more
PRIMARY SOURCE:
Mora S. Rosuvastatin for the primary prevention of cardiovascular events in women with elevated hsCRP and Low LDLC: Sex-specific outcomes from the JUPITER Trial. American Heart Assocation 2009; Abstract 1426.
DATE: November 19, 2009
EXCERPT: "A subset analysis of data from the JUPITER trial indicates that apparently healthy women treated with rosuvastatin (Crestor) reduced their relative risk of major cardiovascular events by 46%, slightly higher than the 42% reduction seen in men." more
PRIMARY SOURCE:
Mora S. Rosuvastatin for the primary prevention of cardiovascular events in women with elevated hsCRP and Low LDLC: Sex-specific outcomes from the JUPITER Trial. American Heart Assocation 2009; Abstract 1426.
PRIMARY SOURCE:
Mora S. Rosuvastatin for the primary prevention of cardiovascular events in women with elevated hsCRP and Low LDLC: Sex-specific outcomes from the JUPITER Trial. American Heart Assocation 2009; Abstract 1426.
ADDITIONAL SOURCES:
Pradhan A. Prevention of major cardiovascular events with rosuvastatin among patients with impaired fasting glucose: The JUPITER Trial. American Heart Assocation 2009; Abstract 1425.
Hsia J. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin in the JUPITER Trial. American Heart Assocation 2009; Abstract 1422.
Comments